Application of chemometric techniques in search of clinically applicable biomarkers of disease

Drug Development Research

Volumn 75, Issue 5, 2014, Pages 283-290

  Kotłowska, Alicja ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

biomarker; chemometrics; clinical research; metabolomics; multivariate methods

Indexed keywords

CHEMOMETRIC ANALYSIS; CHEMOMETRICS; DATA ANALYSIS; DISEASE MARKER; HUMAN; METABOLOMICS; PUBLICATION; REVIEW; VALIDATION STUDY; CLASSIFICATION; DISEASES; PROGNOSIS;

BIOLOGICAL MARKER;

BIOMARKERS; DISEASE; HUMANS; METABOLOMICS; PROGNOSIS;

EID: 84906704735     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21213     Document Type: Review

References (68)

1. Amato U, Antoniadis A, Grégoire G,. 2003. Independent component discriminant analysis. Int J Math 3: 735-753.
2. Anderson PE, Reo NV, DelRaso NJ, Doom TE, Raymer ML,. 2008. Gaussian binning: a new kernel-based method for processing NMR spectroscopic data for metabolomics. Metabolomics 4: 261-272.
3. Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, et al. 2011. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 96: 3775-3784.
4. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF,; Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95.
5. Bartel J, Krumsiek J, Theis FJ,. 2013. Statistical methods for the analysis of high-throughput metabolomics data. Comput Struct Biotechnol J 4: e201301009.
6. Blackwood L,. 1995. Normality transformations for environmental data from compound normal-lognormal distributions. Environ Monit Assess 35: 55-75.
7. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M,. 2008. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131: 389-396.
8. Braun J, Sabanés Bové D, Leonhard Held L,. 2014. Choice of generalized linear mixed models using predictive crossvalidation. Comput Stat Data An 75: 190-202.
9. Bravo A, Cases M, Queralt-Rosinach N, Sanz F, Furlong LI,. 2014. A knowledge-driven approach to extract disease-related biomarkers from the literature. Biomed Res Int 2014: 253128. doi: 10.1155/2014/253128.
10. Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J,. 2007. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometr 20: 341-351.
11. Camacho J, Ferrer A,. 2014. Cross-validation in PCA models with the element-wise k-fold (ekf) algorithm: practical aspects. Chemometr Intell Lab 131: 37-50.
12. Chung L, Shibli S, Moore K, Elder EE, Boyle FM, Marsh DJ, Baxter RC,. 2013. Tissue biomarkers of breast cancer and their association with conventional pathologic features. Brit J Cancer 108: 351-360.
13. Damman P, Beijk MA, Kuijt WJ, Verouden NJ, van Geloven N, Henriques JP, Baan J, Vis MM, Meuwissen M, van Straalen JP, et al. 2011. Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 57: 29-36.
14. De Mees C, Bakker J, Szpirer J, Szpirer C,. 2006. Alpha-fetoprotein: from a diagnostic biomarker to a key role in female fertility. Biomark Insights 1: 82-85.
15. Derde MP, Massart DL, Ooghe W, De Waele A,. 1983. Use of pattern-recognition display techniques to visualize the data contained in complex data-bases. A case study. J Automat Chem 5: 136-145.
16. Di Gangi IM, Vrhovsek U, Pazienza V, Mattivia F,. 2014. Analytical metabolomics-based approaches to pancreatic cancer. Trends Anal Chem 55: 94-116.
17. Duarte IF, Diaz SO, Gil MA,. 2014. NMR metabolomics of human blood and urine in disease research. J Pharm Biomed Anal 93: 17-26.
18. Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E, Lindgren F, Long I, Lundstedt T, Trygg J, Wold S,. 2004. Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 380: 419-429.
19. Geurts P, Irrthum A, Wehenkel L,. 2009. Supervised learning with decision tree-based methods in computational and systems biology. Mol Biosyst 5: 1593-1605.
20. Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, Dahl S, Gribbestad IS, Bathen TF,. 2010. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 9: 972-979.
21. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB,. 2004. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 22: 245-252.
22. Gowda GAN, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D,. 2008. Metabolomics-based methods for early disease diagnostics: a review. Expert Rev Mol Diagn 8: 617-633.
23. Hendrickson EL, Lamont RJ, Hackett M,. 2008. Tools for interpreting large-scale protein profiling in microbiology. J Dent Res 87: 1004-1015.
24. Hill M, Parízek A, Kancheva R, Dusková M, Velíková M, Kríz L, Klímková M, Pasková A, Zizka Z, Matucha P, et al. 2010. Steroid metabolome in plasma from the umbilical artery, umbilical vein, maternal cubital vein and in amniotic fluid in normal and preterm labor. J Steroid Biochem Mol Biol 121: 594-610.
25. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW, Nolden BM, Gross S, Schreiber D, Nicholson JK, et al. 2006. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 3: e327.
26. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, IThompson IM, Weiss RH,. 2009. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 8: 558-570.
27. Kim Y, Koo I, Jung BH, Chung BC, Lee D,. 2010. Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinformatics 11: S4.
28. Konieczna L, Ba̧czek T, Belka M, Fel A, Markuszewski M, Struck W, Markuszewski M, Kaliszan R,. 2012. Steroid profiles as potential biomarkers in patients with urogenital tract cancer for diagnostic investigations analyzed by liquid chromatography coupled to mass spectrometry. J Pharm Biomed Anal 73: 108-115.
29. Kotłowska A,. 2012. Application of steroid hormone metabolomics in search of biomarkers in clinical research. Drug Dev Res 73: 381-389.
30. Kotłowska A, Maliński E, Sworczak K, Kumirska J, Stepnowski P,. 2009. The urinary steroid profile in patients diagnosed with adrenal incidentaloma. Clin Biochem 42: 448-454.
31. Kotłowska A, Sworczak K, Stepnowski P,. 2011. Urine metabolomics analysis for adrenal incidentaloma activity detection and biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci 15: 359-363.
32. Lerma C, Martinez A, Ruiz N, Vargas A, Oscar Infante O, Martinez-Lavin M,. 2011. Nocturnal heart rate variability parameters as potential fibromyalgia biomarker: correlation with symptoms severity. Arthritis Res Ther 13: R185.
33. Li Y, Nie L, Jiang H, Lin J, Zhou H, Xie J, Qu Z, Qi D, Zhang Y,. 2013. Metabonomics study of essential hypertension and its Chinese medicine subtypes by using gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy. Evid Based Complement Alternat Med 2013: 625906.
34. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK,. 2004. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 9: 1-31.
35. Llorach-Asunciõn R, Jauregui O, Urpi-Sarda M, Andres-Lacueva C,. 2010. Methodological aspects for metabolome visualization and characterization: a metabolomic evaluation of the 24 h evolution of human urine after cocoa powder consumption. J Pharm Biomed Anal 51: 373-381.
36. Madsen R, Lundstedt T, Trygg J,. 2010. Chemometrics in metabolomics-a review in human disease diagnosis. Anal Chim Acta 659: 23-33.
37. Mayeux R,. 2004. Biomarkers: potential uses and limitations. NeuroRx 1: 182-188.
38. Meigs JB,. 2009. Multiple Biomarker Prediction of Type 2 Diabetes. Diabetes Care 32: 1346-1348.
39. Mkhadri A, Celeux G, Nasroallah A,. 1997. Regularization in discriminant analysis: an overview. Comput Stat Data An 23: 403-423.
40. Monteiro MS, Carvalho M, Bastos ML, Guedes de Pinho P,. 2013. Metabolomics analysis for biomarker discovery: advances and challenges. Curr Med Chem 20: 257-271.
41. Montoliu I, Martin FP, Collino S, Rezzi S, Kochhar S,. 2009. Multivariate modeling strategy for intercompartmental analysis of tissue and plasma 1H NMR spectrotypes. J Proteome Res 8: 2397-2406.
42. Nicholson JK, Lindon JC, Holmes E,. 1999. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181-1189.
43. Nielsen NPV, Carstensen JM, Smedsgaard J,. 1998. Aligning of single and multiple wavelength chromatographic profiles for chemometric data analysis using correlation optimised warping. J Chromatogr A 805: 17-35.
44. Nyamundanda G, Brennan L, Gormley IC,. 2010. Probabilistic principal component analysis for metabolomic data. BMC Bioinformatics 11: 571.
45. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM,. 2012. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 4: 127rv3.
46. Ramadan Z, Jacobs D, Grigorov M, Kochhar S,. 2006. Metabolic profiling using principal component analysis, discriminant partial least squares, and genetic algorithms. Talanta 68: 1683-1691.
47. Rantalainen M, Bylesjö M, Cloarec O, Nicholson JK, Holmes E, Trygg J,. 2007. Kernel-based orthogonal projections to latent structures (K-OPLS). J Chemometr 21: 376-385.
48. Ringnér M, Peterson C, Khan J,. 2002. Analyzing array data using supervised methods. Pharmacogenomics 3: 403-415.
49. Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, Páez de la Cadena M,. 2007. Improvements in the search for potential biomarkers by proteomics: application of principal component and discriminant analyses for two-dimensional maps evaluation. J Chromatogr B Analyt Technol Biomed Life Sci 849: 251-260.
50. Rousseau R, Govaerts B, Verleysen M, Boulanger B,. 2008. Comparison of some chemometric tools for metabonomics biomarker identification. Chemometr Intell Lab Syst 91: 54-66.
51. Sato S, Arita M, Soga T, Nishioka T, Tomita M,. 2008. Time-resolved metabolomics reveals metabolic modulation in rice foliale. BMC Syst Biol 2: 51.
52. Schaffer C,. 1993. Selecting a classification method by cross-validation. Mach Learn 13: 135-143.
53. Shlomi T, Cabili MN, Ruppin E,. 2009. Predicting metabolic biomarkers of human inborn errors of metabolism. Mol Syst Biol 5: 263.
54. Struck W, Wiczling P, Waszczuk-Jankowska M, Kaliszan R, Markuszewski MJ,. 2012. New supervised alignment method as a preprocessing tool for chromatographic data in metabolomic studies. J Chromatogr A 1256: 150-159.
55. Tate J, Ward G,. 2004. Interferences in immunoassay. Clin Biochem Rev 25: 105-120.
56. Vanwinckelen G, Blockeel H, 2012. On estimating model accuracy with repeated cross-validation. BeneLearn 2012: Proceedings of the 21st Belgian-Dutch Conference on Machine Learning: 39-44.
57. Vasan RS,. 2006. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113: 2335-2362.
58. Vinken M, Maes M, Vanhaecke T, Rogiers V,. 2013. Drug-induced liver injury: mechanisms, types and biomarkers. Curr Med Chem 20: 3011-3021.
59. Wilkinson JD, Williams PL, Leister E, Zeldow B, Shearer WT, Colan SD, Siberry GK, Dooley LB, Scott GB, Rich KC, et al. 2013. Cardiac biomarkers in HIV-exposed uninfected children. AIDS 27: 1099-1108.
60. Wishart DS,. 2007. Current progress in computational metabolomics. Brief Bioinform 8: 279-293.
61. Wrotek SE, Kozak WE, Hess DC, Fagan SC,. 2011. Treatment of fever after stroke: conflicting evidence. Pharmacotherapy 31: 1085-1091.
62. Wudy SA, Wachter UA, Homoki J, Teller WM,. 1995. 17 alpha- hydroxyprogesterone, 4-androstenedione, and testosterone profiled by routine stable isotope dilution/gas chromatography-mass spectrometry in plasma of children. Pediatr Res 38: 76-80.
63. Xia J, Broadhurst DI, Wilson M, Wishart DS,. 2013. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 9: 280-299.
64. Yang J, Xu G, Hong Q, Liebich HM, Lutz K, Schmülling RM, Wahl HG,. 2004. Discrimination of type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. J Chromatogr B Analyt Technol Biomed Life Sci 813: 53-58.
65. Yata K, Aoshima M,. 2012. Effective PCA for high-dimension, low-sample-size data with noise reduction via geometric representations. J Multivariate Anal 105: 193-215.
66. Zhang L, Xiao H, Wong DT,. 2009. Salivary biomarkers for clinical applications. Mol Diagn Ther 13: 245-259.
67. Zheng B, Agresti A,. 2000. Summarizing the predictive power of a generalized linear model. Stat Med 19: 1771-1781.
68. Zimmerman J, Fromm R, Meyer D, Boudreaux A, Wun CC, Smalling R, Davis B, Habib G, Roberts R,. 1999. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation 99: 1671-1677.